Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.

Steiner D, Munera C, Hale M, Ripa S, Landau C.

J Pain. 2011 Nov;12(11):1163-73. doi: 10.1016/j.jpain.2011.06.003. Epub 2011 Jul 31.

PMID:
21807566
2.

Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.

Steiner DJ, Sitar S, Wen W, Sawyerr G, Munera C, Ripa SR, Landau C.

J Pain Symptom Manage. 2011 Dec;42(6):903-17. doi: 10.1016/j.jpainsymman.2011.04.006. Epub 2011 Sep 25.

PMID:
21945130
3.

Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.

Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.

Clin Ther. 2007 Oct;29(10):2179-93. Erratum in: Clin Ther. 2009 Mar;31(3):677.

PMID:
18042474
4.

Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.

Miller K, Yarlas A, Wen W, Dain B, Lynch SY, Brennan MJ, Ripa SR.

Expert Opin Pharmacother. 2013 Feb;14(3):269-77. doi: 10.1517/14656566.2013.767331.

PMID:
23374027
5.

A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain.

Yarlas A, Miller K, Wen W, Dain B, Lynch SY, Pergolizzi JV, Raffa RB, Ripa SR.

J Pain. 2013 Jan;14(1):14-23. doi: 10.1016/j.jpain.2012.09.016. Epub 2012 Nov 29.

PMID:
23200931
6.

Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials.

Yarlas A, Miller K, Wen W, Lynch SY, Ripa SR, Pergolizzi JV, Raffa RB.

Pain Pract. 2016 Mar;16(3):345-58. doi: 10.1111/papr.12281. Epub 2015 Jan 20.

PMID:
25599968
8.

Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain.

Yarlas A, Miller K, Wen W, Lynch SY, Munera C, Pergolizzi JV Jr, Raffa R, Ripa SR.

Postgrad Med. 2015 Jan;127(1):38-45. Epub 2014 Dec 15.

PMID:
25526229
9.

A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain.

Ripa SR, McCarberg BH, Munera C, Wen W, Landau CJ.

Expert Opin Pharmacother. 2012 Jun;13(9):1229-41. doi: 10.1517/14656566.2012.667073. Epub 2012 Mar 12.

PMID:
22409388
10.

Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels.

Kapil RP, Cipriano A, Friedman K, Michels G, Shet MS, Colucci SV, Apseloff G, Kitzmiller J, Harris SC.

J Pain Symptom Manage. 2013 Jul;46(1):65-75. doi: 10.1016/j.jpainsymman.2012.06.014. Epub 2012 Sep 29.

PMID:
23026548
11.
12.

Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain.

Gordon A, Rashiq S, Moulin DE, Clark AJ, Beaulieu AD, Eisenhoffer J, Piraino PS, Quigley P, Harsanyi Z, Darke AC.

Pain Res Manag. 2010 May-Jun;15(3):169-78.

15.
16.

The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and health.

Miller K, Yarlas A, Wen W, Dain B, Lynch SY, Ripa SR, Pergolizzi JV Jr, Raffa R.

Clin J Pain. 2014 Dec;30(12):1015-22. doi: 10.1097/AJP.0000000000000068.

PMID:
24394747
18.

Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis.

Wen W, Lynch SY, Munera C, Swanton R, Ripa SR, Maibach H.

Expert Opin Drug Saf. 2013 May;12(3):309-19. doi: 10.1517/14740338.2013.780025. Epub 2013 Mar 19.

PMID:
23506252
19.

Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.

Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K, Ruckes C, Weber S, Grothe B, Fleischer W, Reimer K.

J Pain. 2008 Dec;9(12):1144-54. doi: 10.1016/j.jpain.2008.06.014. Epub 2008 Aug 16.

PMID:
18708300

Supplemental Content

Support Center